Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Trading time left in December/2020

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Dec 08, 2020 8:05am

198 Views

Post# 32056288

RE:Trading time left in December/2020

narmac, I believe that Don M does not follow any timeline on the calendar. He flies by the seat of his pants. So he'll come out with whatever news announcement when you least expect it. So the best anyone can do, be ready. Buy what you can afford and sit back and enjoy the ride or not. Our attempt to analyze him becomes an exercise of futility, a total waste of time.

As you know, RVX is not for the faint-hearted. We stuck around this far. We might as well see how this ends.

glta
G1945V

<< Previous

Bullboard Posts

Next >>

New CEO leads Sonoro Energy's vision to expand in MENA